From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
From Vaccines to Oncology and Beyond: Tracking mRNA’s Progress
In this article, ICON’s Andreas Dreps and Martin Lachs discuss how the success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
-
Practical considerations for managing cell and gene therapy supply chains
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
-
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
©BioPharm International
-
Challenges of expanding CAR-T Cell Therapy into solid tumors
Learn more about the challenges associated with developing CAR-T therapies for solid tumors in this article.
© Huber, B.; Joeckel, T. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors. BioPharm International 2023, 36 (5), 22–23,27
-
CAR-T cell therapy in oncology
In this article,Brian HuberandTamie Joeckel, consider how cell and gene therapies could change the future of cancer treatments and bring new options to patients.
-
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
-
Cell and gene therapy specific market authorisation guidances
Brandon Fletcher, Principal, Cell and Gene Therapy, offers his insights on the key changes in regulatory guidance documents released by the US Food and Drug Agency.
-
Improving early phase oncology clinical trial design using Bayesian-based BOIN and BOP2 designs
Tim Clark, VP Drug Development Solutions, Martin Lachs, VP Project Management Oncology & Cell Therapeutics and Alan Phillips, Sr. Director Biostatistics, offer insights on selecting and implementing the appropriate model-based or model-assisted design for early phase oncology trials.
-
4D pharma enlists ICON for upcoming phase I/II microbiome therapeutic combo study in urothelial carcinoma with Merck KGaA’s Bavencio
This article announces that 4D Pharma are working with ICON for an upcoming trial with its lead live biotherapeutic MRx0518 in combination with Merck KGaA’s Bavencio. (a subcription is required to view this article)
-
Panel discussion: setting the roadmap for optimising cancer clinical trials
In this podcast, Martin Lachs discusses how clinical trials have been the backbone of cancer research.
